Emerging role of competing endogenous RNA in lung cancer drug resistance

Abstract

Lung cancer remains one of the most common malignant cancers worldwide, and its survival rate is extremely low. Chemotherapy, the mainstay of lung cancer treatment, is not as effective as it could be due to the development of cellular resistance. The molecular mechanisms of drug resistance in lung cancer remain to be elucidated. Accumulating evidence suggests that ceRNAs are involved in various carcinogenesis and development. CeRNA is a transcript that regulates each other through competition with miRNA. However, the relationship between ceRNAs and chemoresistance in lung cancer remains unclear. In this narrative review, we provided a summary of treatment approaches that focus on ceRNA networks to overcome drug resistance.

Keywords:

• Lung cancer
• drug resistance
• ceRNAs
• tKI
• cisplatin
• non-coding RNA

Disclosure statement

The authors declare that they have no competing interests.

Additional information

Funding

This work was funded by the Hengyang City Science and Technology Planning Project [grant number 202150063473], the Scientific Research Project of Hunan Provincial Health Commission [grant number 202202044140], the Scientific Research Project of Hunan Provincial Education Department [grant number 21B0438].